Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

Bibliographic Details
Main Authors:	Shelledy, Lindsay, Roman, Danielle
Format:	Online
Language:	English
Published:	Harborside Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677808/

Similar Items

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
by: Borch, Troels Holz, et al.
Published: (2014)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
by: Fisher, Rosalie, et al.
Published: (2012)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
by: Maleka, A., et al.
Published: (2016)

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
by: Gavric Ana Ursula, et al.
Published: (2018-01-01)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
by: Sponghini, Andrea P, et al.
Published: (2015)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
by: Amin, Asim, et al.
Published: (2016)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
by: Sahadudheen, K., et al.
Published: (2016)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
by: Nowara, Elzbieta, et al.
Published: (2016)

Metastatic melanoma and vemurafenib: novel approaches
by: De Mello, Ramon Andrade
Published: (2012)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
by: Aylwin, Simon J. B., et al.
Published: (2015)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma12
by: Kim, Hee Kyung, et al.
Published: (2016)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
by: Spagnolo, Francesco, et al.
Published: (2014)

Clinical significance of BRAF mutations in metastatic melanoma
by: Chang, David Z, et al.
Published: (2004)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
by: Tahiri, Andliena, et al.
Published: (2013)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
by: Ascierto, Paolo A, et al.
Published: (2015)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
by: Chan, Sze Wai, et al.
Published: (2015)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
by: Sondermann, Wiebke, et al.
Published: (2015)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
by: Joshi, Monika, et al.
Published: (2015)

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
by: Swaika, Abhisek, et al.
Published: (2014)

Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib
by: Houriet, Carine, et al.
Published: (2014)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
by: Goodall, Megan L, et al.
Published: (2014)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
by: Joseph I. Clark, et al.
Published: (2018-07-01)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
by: Tate, Sonya C, et al.
Published: (2016)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
by: Curl, Patti, et al.
Published: (2015)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
by: Curl, Patti, et al.
Published: (2014)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek, Tanja, et al.
Published: (2016)

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
by: Kopetz, Scott, et al.
Published: (2015)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
by: Capalbo, Carlo, et al.
Published: (2014)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
by: Barnhart, Carrie
Published: (2015)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
by: Satzger, Imke, et al.
Published: (2015)

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma
by: Sarnaik, Amod, et al.
Published: (2015)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
by: Castellani, Elisa, et al.
Published: (2012)

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
by: Wolf, Sanne EJ, et al.
Published: (2013)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
by: Cooper, Zachary A., et al.
Published: (2013)

Correction: Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
Published: (2015)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
by: Garrisi, Vito Michele, et al.
Published: (2014)

Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
by: McGettigan, Suzanne
Published: (2014)

A STATement on Vemurafenib-Resistant Melanoma
by: Hartsough, Edward J., et al.
Published: (2013)